Buy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth Opportunities

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report), reducing the price target to $6.00.

Michael Okunewitch has given his Buy rating due to a combination of factors, including BioRestorative Therapies’ innovative approach in developing cell-based therapies, and a strategic supply agreement that could contribute to the company’s revenue streams. The company’s core programs involve advanced therapies using adult stem cells, which are at the forefront of medical innovation, particularly their BRTX-100 and ThermoStem products. These products address significant medical conditions and represent a strong potential for growth and patient benefit.

Moreover, the recent five-year supply agreement with Cartessa Aesthetics positions BioRestorative Therapies well within the aesthetics industry—a rapidly expanding market. The collaboration is expected to yield significant revenues that could offset the costs associated with the development of their core programs. The valuation method applied by Okunewitch takes into account the potential risks and rewards of the company’s product pipeline, applying a balanced view with risk adjustments and a discount rate that factors in the developmental stage and clinical trial risks, leading to a positive outlook on the stock’s future performance.

In another report released on April 16, Roth MKM also maintained a Buy rating on the stock with a $15.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BRTX in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

BioRestorative Therapies (BRTX) Company Description:

Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The company is developing the following scientific initiatives: brtxDISC Program offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. The ThermoStem Program focuses on treatments for metabolic disorders and obesity and uses brown fat stem cells, which initial research indicates increased caloric burning and reduced glucose and lipid levels in the body. It also offers plant stem cell-based facial creams and products under the Stem Pearls brand. Biorestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.